Morgan Stanley
CTNM

Morgan Stanley’s Contineum Therapeutics CTNM Stock Holding History

Morgan Stanley’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$846K Sell
51,618
-19,183
-27% -$251K ﹤0.01% 5288
2026
Q1 		$925K Sell
70,801
-53,485
-43% -$717K ﹤0.01% 5182
2025
Q4 		$1.42M Buy
124,286
+31,291
+34% +$357K ﹤0.01% 5008
2025
Q3 		$1.09M Buy
92,995
+93
+0.1% +$750 ﹤0.01% 5130
2025
Q2 		$369K Buy
92,902
+35,745
+63% +$155K ﹤0.01% 5602
2025
Q1 		$399K Buy
57,157
+30,601
+115% +$278K ﹤0.01% 5432
2024
Q4 		$389K Buy
26,556
+6,159
+30% +$97.5K ﹤0.01% 5526
2024
Q3 		$390K Buy
20,397
+8,537
+72% +$164K ﹤0.01% 5516
2024
Q2 		$209K Buy
+11,860
New +$191K ﹤0.01% 5656

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley's CTNM Position: Q2 2026 in Review

Morgan Stanley reduced its Contineum Therapeutics (CTNM) stake by 27% in Q2 2026, selling an estimated $251K and leaving 51,618 shares worth $846K. The position accounts for ﹤0.01% of the portfolio, ranked #5288.

Morgan Stanley first reported a position in CTNM in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.42M in Q4 2025. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Morgan Stanley held 51,618 shares of Contineum Therapeutics worth $846K as of Q2 2026.
  • Morgan Stanley sold 19,183 Contineum Therapeutics shares in Q2 2026, an estimated $251K.
  • Contineum Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5288 holding.
  • Morgan Stanley first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Morgan Stanley's Contineum Therapeutics position peaked at $1.42M in Q4 2025.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.